Role of chemokines, their gene polymorphisms in resectable NSCLC

Objectives: Chemokines are a part of immune reaction targeted against tumor. Chemokine expression is influenced by gene polymorphisms. Their role isn9t clear in resectable NSCLC. Aim: To compare chemokine concentrations (CCL2, CCL8, CXCL12) in plasma of patients with resectable NSCLC to those without cancer. To find out whether the chemokine concentrations differ according to stage of the disease. To assess gene polymorphisms CCL2 rs3760396, CCL8 rs3138035, CXCL12 rs1804429. To find out whether the gene polymorphisms differ between NSCLC patients and those without cancer. Material and Methods: We enrolled 69 patients undergoing surgery for NSCLC (37 males- mean age 66 years, 32 females- mean age 64 years). They underwent standard diagnostic and staging procedure. We diagnosed 42 patients with NSCLC, 27 patients had benign lung pathologies (control group). We assessed chemokine concentrations in peripheral blood by ELISA LSBio Kits. We assessed gene polymorphisms by quantitative real- time polymerase chain reaction with TaqMan hydrolysis probes. Parametric statistics was used for analysis. Results: There was no difference in concentrations of chemokines in plasma of NSCLC patients and control group. The CXCL12 concentrations positively corelated with the tumor extent expressed by clinical stage (mean values: stage I 5.08ng/ml; SEM 0.59; stage II and IIIA 7.82ng/ml; SEM 1.06; p= 0.022). There was no difference in gene polymorphisms between NSCLC patients and control group (CCL2 rs3760396 p= 0.160; CCL8 rs3138035 p= 0.589; CXCL12 rs1804429 p= 0.233). Conclusion: The CXCL12 relates tumor growth and might be a biomarker of advanced disease. We might need to include more patients to find out more about gene polymorphisms.